The Legal Status of Compounded GLP-1s in 2026: What Actually Changed
Compounded GLP-1s are not banned, but the pathway that produced the 2023–24 market is closed. The FDA declared the semaglutide shortage resolved on 21 February 2025, ending the enforcement discretion that let outsourcing facilities compound it at scale. What remains is 503A compounding for an individual patient where a prescriber documents a clinical reason the approved product does not serve them.
What changed, and when
| Date | What happened | Effect |
|---|---|---|
| 2022–2024 | Semaglutide and tirzepatide on the FDA shortage list | Enforcement discretion allowed large-scale compounding |
| Late 2024 | Tirzepatide shortage declared resolved | The tirzepatide mass-compounding window closed first |
| 21 Feb 2025 | Semaglutide shortage declared resolved | Enforcement discretion ended |
| 2025–2026 | Warning letters, import alerts, state board actions | Enforcement through multiple channels at once |
| 2026 | 503A patient-specific compounding continues | Requires a documented clinical reason |
Compiled 4 August 2026. Regulatory status changes; verify with the FDA before relying on it.
503A and 503B are not the same thing
| 503A | 503B | |
|---|---|---|
| What it is | A traditional pharmacy | An outsourcing facility |
| Compounds for | A named individual patient | Batches, often without patient names |
| Requires a prescription | Yes, patient-specific | Not necessarily |
| Manufacturing standard | State board oversight | cGMP, FDA-registered |
| GLP-1s after Feb 2025 | Permitted with a documented clinical reason | Mass compounding no longer covered |
This distinction decides whether a given programme is operating inside the framework.
Salt forms: the specific thing regulators objected to
The FDA has said that semaglutide sodium and semaglutide acetate are not the same active ingredient as the base form used in approved products, and are not appropriate for compounding. This is not a technicality about naming. A salt form has not been evaluated for the safety and efficacy that the approved product's trials established.
Ask for the exact form and concentration in writing, in mg/mL. Of the providers we track, very few publish it, and it is the single most useful question a buyer can ask.
The gap that justified compounding on cost grounds has narrowed sharply since 2024.
What this means in practice
- A programme that operates as though nothing changed in February 2025 deserves extra diligence. The pathway it was built on closed.
- "Personalised dosing" is not automatically a clinical reason. The documented justification has to be specific to the patient.
- Price the approved routes first. An approved oral tablet at $149 has changed this calculation more than any compounded price has.
- Availability can change without notice. Enforcement has been active throughout 2026.
Enforcement runs through four channels, not one
People tend to picture enforcement as the FDA banning something. In practice it arrives through several routes at once, and a provider can be operating legally under one while exposed under another.
| Channel | Who acts | What it looks like |
|---|---|---|
| Federal drug law | FDA | Warning letters, import alerts, injunctions |
| State pharmacy boards | State regulators | Licence conditions, suspensions |
| Advertising law | FTC and state AGs | Action on unsubstantiated claims |
| Trademark and patent | Manufacturers | Civil suits against sellers |
A provider can satisfy one and fail another. Checking only the FDA misses three of four.
What a documented clinical reason actually looks like
The 503A route requires a prescriber to determine that a compounded preparation is necessary for a specific patient. Examples that plainly qualify: a documented allergy to an excipient in the approved product, or a dose that is not commercially available and is clinically indicated.
What does not qualify on its face: a preference for a lower price, or a marketing claim that personalised dosing is inherently superior. The distinction is not pedantic — it is the whole basis on which the remaining pathway operates.
The questions that separate programmes, in order of usefulness
- Which pharmacy fills this, and under 503A or 503B? A name can be checked. A refusal to name removes your only independent verification route.
- What is the exact salt form and concentration, in mg/mL? The FDA has said sodium and acetate forms are not the same active ingredient as the base form.
- What is the price at a maintenance dose? Not the advertised starter figure.
- What is refundable if I stop during titration? That is where discontinuation concentrates.
- Is there a membership fee separate from the medication? It is frequently outside the headline price.
What could change next
- Bulks-list decisions. The FDA's Category 1 and 2 lists determine what may be compounded at all, and they are revised.
- State-level action. Boards move independently of federal timelines.
- Approved-product pricing. Every cut to the self-pay price narrows the argument for compounding on cost grounds, and there have been several.
The reasonable position for a buyer is that this pathway is legal but narrowed and actively enforced, and that availability from any given provider can change without notice.
What "FDA-approved pharmacy" means, and why nobody has one
A phrase that appears in marketing and cannot be true as written. The FDA does not approve pharmacies. It approves drugs. Pharmacies are licensed by state boards; 503B outsourcing facilities register with the FDA, which is registration rather than approval of what they make.
So a programme claiming an "FDA-approved compounded" product is describing something that does not exist. That is not a technicality — it is the clearest single tell that a seller is either confused about the framework or relying on you being.
How to check a pharmacy yourself, in about five minutes
- Get the name. Everything below requires it, which is why a refusal to name is decisive.
- State board licence lookup. Every state board publishes a searchable register with licence status and disciplinary history.
- FDA warning-letter database. Searchable by company name.
- 503B registration list, if they claim to be one. The FDA publishes the registered facilities.
- Recall database. openFDA covers drug recalls by firm.
Five minutes, all free, all primary sources. It is the single highest-value check available to a buyer, and it is impossible without a name.
What this page does not settle
- Whether any specific programme is compliant. That depends on its pharmacy, its prescribing practice and its documentation, none of which is visible from outside.
- How enforcement will develop. It has been active through 2026 across four channels.
- Whether a compounded preparation performs like the approved product. No trial has tested one, and no figure on this site transfers to one.